Thus, although the cell type undergoing changes in cell senescence in the PD model remains to be identified, our findings collectively suggest that SGK1 inhibition could be used to treat PD by suppressing the glial activation of inflammation, especially the NLRP3‐inflammasome, and cellular senescence (Appendix Fig S9). The gene discussed is NLRP3; the disease is Parkinson disease.